[PDF] Top 20 Therapeutic targets in systemic sclerosis
Has 10000 "Therapeutic targets in systemic sclerosis" found on our website. Below are the top 20 most common "Therapeutic targets in systemic sclerosis".
Therapeutic targets in systemic sclerosis
... The clinical heterogeneity of SSc makes it likely that different pathogenic processes operate in different disease subsets. Diffuse cutaneous SSc (dcSSc) has a much more inflam- matory onset than does limited cutaneous ... See full document
5
Whole-genome bisulfite sequencing in systemic sclerosis provides novel targets to understand disease pathogenesis
... Genome-wide DNA methylation analysis in dermal fibroblasts from patients with diffuse and limited systemic sclerosis reveals common and subset-specific DNA methylation aberrancies. Ann R[r] ... See full document
12
Therapeutic and diagnostic outcomes of a standardised, comprehensive care pathway for patients with systemic sclerosis
... or therapeutic interventions were initiated in 191 (85%) of the ...direct therapeutic intervention was expected following RHC, the multidisciplinary PAH group advised to repeat echocardiography within 6 – ... See full document
11
Pressure and pain In Systemic sclerosis/Scleroderma an evaluation of a simple intervention (PISCES): randomised controlled trial protocol
... with Systemic Sclerosis (SSc)/Scleroderma have been reported to be both common and ...with Systemic Sclerosis can be improved through the provision of a simple pressure-relieving ...provided ... See full document
8
<p>Epidemiology of systemic sclerosis and systemic sclerosis-associated interstitial lung disease</p>
... of therapeutic treatment for SSc and SSc- associated ILD (SSc-ILD) is to improve quality of life by minimizing speci fi c organ involvement and subsequent life-threatening ... See full document
17
Pressure and pain In Systemic sclerosis/Scleroderma - an evaluation of a simple intervention (PISCES): randomised controlled trial protocol
... with Systemic Sclerosis (SSc)/Scleroderma have been reported to be both common and ...with Systemic Sclerosis can be improved through the provision of a simple pressure-relieving ...provided ... See full document
8
Pathogenesis and potential therapeutic targets in systemic lupus erythematosus: from bench to bedside
... experience and several open case series suggested a clinical improvement and a consistent reduction of SLE activity disease index (SLEDAI, BILAG) when this biological agent was used for SLE patients [105]. However, two ... See full document
13
Pathogenesis and Therapeutic Targets of Cholangiocarcinoma
... prior systemic therapy for metastatic disease, PFS and OS were ...that targets both Raf and VEGF receptor tyrosine kinase ...potential therapeutic use for cholangiocarcinoma ... See full document
6
Metalloproteinases and their inhibitors as therapeutic targets for multiple sclerosis: current evidence and future perspectives
... Numerous challenges affect the medical community for the treatment of multiple sclerosis (MS), since there are no drugs able to cure this disease. MS treatment typically focuses on slowing the progression of the ... See full document
13
Stress granules and RNA processing bodies are novel autoantibody targets in systemic sclerosis
... Anti-UPF1 antibody was kindly provided by Dr. Lynne Maquat (University of Rochester Medical Center, Roch- ester, NY, USA). Antibodies to MOV10 and CAPRIN1 were purchased from Proteintech (Chicago, IL, USA); antibodies to ... See full document
13
Immunosuppression for interstitial lung disease in systemic sclerosis
... While the use of corticosteroids alone is recommended for idiopathic pulmonary fibrosis, several warnings about the onset of scleroderma renal crisis have significantly limited their use in SSc [28–31]. However, in ... See full document
8
Comprehensive Analysis of 20 Cases of Systemic Sclerosis
... Progressive Systemic sclerosis was coined by Goetz 1 ...of Systemic sclerosis versus Morphea in an extensive clinical study in 1930 5 ... See full document
151
The incidence, prevalence and survival of systemic sclerosis in the UK Clinical Practice Research Datalink
... of systemic sclerosis attending their clinics and reporting this to the authors [1, 31], or on physician recall [5] which are not as reliable as prospectively recorded diag- noses in the patient’s general ... See full document
9
Systemic sclerosis sine scleroderma
... Systemic sclerosis is a rare generalized disease with scleroderma, ...as systemic sclerosis sine scleroderma (ssSSc) is a very rare subset characterized by the total or partial ab- sence of ... See full document
6
Genetic factors in systemic sclerosis
... A number of genetic loci have been identified that appear to be associated with systemic sclerosis (SSc; scleroderma). There is mounting evidence suggesting that these genetic associations may in fact be ... See full document
7
Clinical Profile of Systemic Sclerosis
... CT Chest Patient No.1 Exertional dyspnea B/L basal Haziness Interstitial lung disease Patient No.2 Exertional dyspnea B/L basal Haziness Patient No.3 Exertional dyspnea Normal study Exer[r] ... See full document
81
Rituximab in early systemic sclerosis
... Figure 3 Change in mean extent of lung tissue and lung tissue with ground glass or reticular pattern involvement from baseline to 12 months follow-up in patients with systemic sclerosis.[r] ... See full document
11
Genetic polymorphisms in systemic sclerosis
... In 1988 a 21 amino-acid (AA) factor with a potent vasocontrictive action was first isolated from cultured porcine aortic endothelial cells and called endothelin (EDN) (Yanagisawa et al., 1988). In the following years the ... See full document
260
Pulmonary hypertension in systemic sclerosis and systemic lupus erythematosus
... of systemic sclerosis (SSc) and systemic lupus erythe- matosus (SLE) [1, 2]; however, it can occur in other connective tissue diseases, including SSc-SLE over- lap syndrome [3], mixed connective ... See full document
10
Cartilage oligomeric matrix protein induced complement activation in systemic sclerosis
... We have confirmed in a large patient cohort that COMP- C3b levels are elevated in patients with SSc compared to healthy controls. The fact that there is no difference in serum COMP-C3b between patients with dcSSc and ... See full document
8
Related subjects